Jordan Paradise
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jordan Paradise has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Alyssa Valentine
Cook County Health , Chicago, IL
1 shared publicationChristina Ramesh
Loyola University Chicago School of Law , Chicago, IL
1 shared publicationSara Cherny
Ann & Robert H Lurie Children’s Hospital of Chicago , Chicago, IL
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Oxford University Press (OUP) in Journal of Law and the Biosciences
- Vol. 13 (1)
Genetic testing fraud trends
Genetic testing fraud schemes are widespread, impacting patients, healthcare providers, and the US government. Fueled by rapid innovations in genetic testing capabilities and expansion of telehealth services following the pandemic, fraudsters are thriving. The Department of Justice (DOJ) and the Department of Health and Human Services (HHS) enhanced scrutiny of such fraud schemes over a decade ago, and in September 2019, targeted enforcement began with the indictment of 35 individuals on allegations of genetic testing fraud activities totaling $2.1 billion (https://www.justice.gov/archives/opa/pr/federal-law-enforcement-action-involving-fraudulent-genetic-testing-results-charges-against). By the end of 2024, the DOJ and HHS had initiated hundreds of investigations, with litigation across multiple legal jurisdictions involving physicians, telemedicine companies, marketing companies, and genetic testing laboratories. This article investigates the nature and scope of genetic testing fraud and describes the concerted government activity to thwart the proliferation of these schemes. While the actual mechanisms to carry out genetic testing fraud, such as kickbacks and inappropriate coding, are not new, there are multiple characteristics that make this type of healthcare fraud distinctive. We describe three genetic testing features that make genetic testing fraud unique and heighten the potential for fraud on the government: widespread interest in test content; test complexity; and associated billing challenges. The article further contributes to the literature by assessing genetic testing fraud schemes and discussing implications for physicians and the healthcare system, including recommendations to prevent future genetic testing fraud.
- 1 January 2026
- Published by Oxford University Press (OUP) in Journal of Law and the Biosciences
- Vol. 13 (1)
Open AccessGenetic testing fraud trends
Genetic testing fraud schemes are widespread, impacting patients, healthcare providers, and the US government. Fueled by rapid innovations in genetic testing capabilities and expansion of telehealth services following the pandemic, fraudsters are thriving. The Department of Justice (DOJ) and the Department of Health and Human Services (HHS) enhanced scrutiny of such fraud schemes over a decade ago, and in September 2019, targeted enforcement began with the indictment of 35 individuals on allegations of genetic testing fraud activities totaling $2.1 billion (https://www.justice.gov/archives/opa/pr/federal-law-enforcement-action-involving-fraudulent-genetic-testing-results-charges-against). By the end of 2024, the DOJ and HHS had initiated hundreds of investigations, with litigation across multiple legal jurisdictions involving physicians, telemedicine companies, marketing companies, and genetic testing laboratories. This article investigates the nature and scope of genetic testing fraud and describes the concerted government activity to thwart the proliferation of these schemes. While the actual mechanisms to carry out genetic testing fraud, such as kickbacks and inappropriate coding, are not new, there are multiple characteristics that make this type of healthcare fraud distinctive. We describe three genetic testing features that make genetic testing fraud unique and heighten the potential for fraud on the government: widespread interest in test content; test complexity; and associated billing challenges. The article further contributes to the literature by assessing genetic testing fraud schemes and discussing implications for physicians and the healthcare system, including recommendations to prevent future genetic testing fraud.
- Open Access
- 13 January 2023
- Published by American Medical Association (AMA) in JAMA
- Vol. 329 (6) , 461-462
The CRISPR Patent Ruling and Implications for Medicine
This Viewpoint discusses the CRISPR patent ruling, an ongoing patent dispute, and the implications for research and medical innovation.
- 13 January 2023
- Published by American Medical Association (AMA) in JAMA
- Vol. 329 (6) , 461-462
Open AccessThe CRISPR Patent Ruling and Implications for Medicine
This Viewpoint discusses the CRISPR patent ruling, an ongoing patent dispute, and the implications for research and medical innovation.
- 1 July 2021
- Published by Cambridge University Press (CUP) in American Journal of Law & Medicine
- Vol. 47 (2-3) , 157-175
Information Opacity in Biopharmaceutical Innovation Through the Lens of COVID-19
The COVID-19 pandemic has revealed myriad and complex challenges for our national health care system spanning preparedness, response, access, costs, infrastructure, coordination, and medical innovation. These challenges implicate federal, state, and local agencies and actors, as well as international collaborative bodies. One constant throughout the pandemic has been the pressing need for safe and effective diagnostics, prophylactic vaccines, and drug treatments to counter the virus.1 Inarguably, significant problems with the multi-faceted system of drug and vaccine innovation and regulation manifested long before the COVID-19 pandemic.2 The pandemic, however, has laid bare the inextricable connections among federal funding, patents, product review and approval mechanisms, and the eventual medical products and resulting costs.
- 1 July 2021
- Published by Cambridge University Press (CUP) in American Journal of Law & Medicine
- Vol. 47 (2-3) , 157-175
Information Opacity in Biopharmaceutical Innovation Through the Lens of COVID-19
The COVID-19 pandemic has revealed myriad and complex challenges for our national health care system spanning preparedness, response, access, costs, infrastructure, coordination, and medical innovation. These challenges implicate federal, state, and local agencies and actors, as well as international collaborative bodies. One constant throughout the pandemic has been the pressing need for safe and effective diagnostics, prophylactic vaccines, and drug treatments to counter the virus.1 Inarguably, significant problems with the multi-faceted system of drug and vaccine innovation and regulation manifested long before the COVID-19 pandemic.2 The pandemic, however, has laid bare the inextricable connections among federal funding, patents, product review and approval mechanisms, and the eventual medical products and resulting costs.
- Open Access
- 1 January 2020
- Published by Oxford University Press (OUP) in Journal of Law and the Biosciences
- Vol. 7 (1)
COVID-IP: staring down the Bayh–Dole Act with 2020 vision
As the human and economic toll of the COVID-19 coronavirus steadily escalates, there is extreme uncertainty regarding the timeframe for prevention, detection, and treatment. 1 There is also concern about the eventual costs associated with approved products and the barriers to access created by the patent system. Industry, government, and academic collaborations are leading the charge in the discovery race, partnerships which have triggered calls for the activation of the federal governments so–called ``march–in rights'' established in the Bayh–Dole Act. 2 The Bayh–Dole Act dramatically altered the patent protections available to federally funded institutions and initiated a 40-year debate over appropriate incentives for innovation and the scope of the government's authority. The COVID-19 pandemic provides an opportunity to reflect on the purpose and impact of the historic legislation as well as contemplate the implications for our public health future. Patent rights for therapeutic compounds, methods of delivery, and medical diagnostics will significantly impact access to and cost of life-saving innovations. This article examines current calls for the U.S. government to utilize governmental march–in rights to quell concerns about patent monopolization and product pricing in the face of our current pandemic.
- 1 January 2020
- Published by Oxford University Press (OUP) in Journal of Law and the Biosciences
- Vol. 7 (1)
Open AccessCOVID-IP: staring down the Bayh–Dole Act with 2020 vision
As the human and economic toll of the COVID-19 coronavirus steadily escalates, there is extreme uncertainty regarding the timeframe for prevention, detection, and treatment. 1 There is also concern about the eventual costs associated with approved products and the barriers to access created by the patent system. Industry, government, and academic collaborations are leading the charge in the discovery race, partnerships which have triggered calls for the activation of the federal governments so–called ``march–in rights'' established in the Bayh–Dole Act. 2 The Bayh–Dole Act dramatically altered the patent protections available to federally funded institutions and initiated a 40-year debate over appropriate incentives for innovation and the scope of the government's authority. The COVID-19 pandemic provides an opportunity to reflect on the purpose and impact of the historic legislation as well as contemplate the implications for our public health future. Patent rights for therapeutic compounds, methods of delivery, and medical diagnostics will significantly impact access to and cost of life-saving innovations. This article examines current calls for the U.S. government to utilize governmental march–in rights to quell concerns about patent monopolization and product pricing in the face of our current pandemic.